DCLK1 Antibody

Code CSB-PA006548LA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human glioma using CSB-PA006548LA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA006548LA01HU at dilution of 1:100

  • Immunofluorescence staining of MCF-7 cells with CSB-PA006548LA01HU at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) DCLK1 Polyclonal antibody
Uniprot No.
Target Names
DCLK1
Alternative Names
Calcium/calmodulin-dependent protein kinase type I-like CPG16 antibody; CL1 antibody; CLICK1 antibody; Cpg16 antibody; DCDC3A antibody; Dcl antibody; Dclk antibody; Dclk1 antibody; DCLK1_HUMAN antibody; Doublecortin domain-containing protein 3A antibody; Doublecortin-like and CAM kinase-like 1 antibody; Doublecortin-like kinase 1 antibody; KIAA0369 antibody; Serine/threonine-protein kinase DCAMKL1 antibody; Serine/threonine-protein kinase DCLK1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Serine/threonine-protein kinase DCLK1 protein (143-381AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The DCLK1 Antibody (Product code: CSB-PA006548LA01HU) is Non-conjugated. For DCLK1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA006548LB01HU DCLK1 Antibody, HRP conjugated ELISA
FITC CSB-PA006548LC01HU DCLK1 Antibody, FITC conjugated
Biotin CSB-PA006548LD01HU DCLK1 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain. May also participate in functions of the mature nervous system.
Gene References into Functions
  1. DCLK1 plays an important role in cancer progression and is involved in the regulation of miR-200c expression. PMID: 29656186
  2. The expression of DCLK1 was found in low-grade adenomas and increased with worsening severity of dysplasia. DCLK1 expression was highly observed in advanced adenomas, which had a clinically higher malignant potential. PMID: 29475922
  3. High DCLK1 expression is associated with malignant pleural mesothelioma. PMID: 28560410
  4. On the basis of these data, FOXD3 is a potent repressor of DCLK1-S expression in normal cells; loss of FOXD3 in hCCCs/hCRCs allows upregulation of DCLK1-S, imparting a potent invasive potential to the cells PMID: 28851816
  5. Expression levels of phosphorylated cdc25A (p-cdc25A) and phosphorylated Chk1 (p-Chk1), belonging to the ATR pathway, were decreased by treatment with Dclk1 inhibitor LRRK2-IN-1 (LRRK), indicating Dclk1 involvement in the ATR pathway PMID: 29048622
  6. In rectal cancer patients treated with preoperative chemoradiotherapy (CRT), DCLK1 expression was significantly correlated with lymph node metastasis and poor cancer-specific survival. However, in patients treated without preoperative therapy, no such correlation was found. DCLK1 expression can be associated with lymph node metastasis and poor cancer-specific survival in rectal cancer patients who receive CRT. PMID: 29924454
  7. Pancreatic ductal adenocarcinoma patients with DCLK1-positive tumors had significantly shorter survival times than those with DCLK1-negative tumors. PMID: 28883702
  8. DCLK1 plays crucial role in the regulation of epithelial-mesenchymal transition.DCLK1 is highly expressed in pancreatic neuroendocrine tumor. PMID: 28179411
  9. DCLK1 is a prognostic biomarker for shortened survival. Secondly, through inhibition of DCLK1, it may serve as a therapeutic target as well PMID: 28351564
  10. DCLK1 has been identified as a potential target for miR-448 to regulate lung squamous cell carcinoma cells growth. PMID: 28320089
  11. Generated a (doublecortin like kinase 1) DCLK1-S-specific polyclonal antibody (S-isoform specific), and studied its use in screening of colon cancer after colonoscopy. PMID: 28414327
  12. DCLK1 expression was observed in tumor cells in patients with pathological stage I non-small cell lung cancer (NSCLC)and was correlated with adverse prognosis, especially in patients with adenocarcinoma. DCLK1 may be a potential new therapeutic target PMID: 28382517
  13. Biochemical and structural characterization of DCLK1 allowed for the mapping of cancer-causing mutations within the kinase domain. PMID: 27545623
  14. Hence, we outline and discuss emerging evidence that strongly supports tuft cells as key regulatory cells in the complex network of the intestinal microenvironment. [review] PMID: 28684459
  15. Our results indicate that Dclk1 is essential in advancing intestinal tumorigenesis. Knocking down Dclk1 decreases tumor stemness and progression and is thus predicted to regulate pro-survival signaling and tumor cell pluripotency. PMID: 28148261
  16. The univariate and multivariate analyses suggested DCAMKL1 protein overexpression was an unfavorable prognostic factor in bladder cancer patients. In conclusion, DCAMKL1 is an independent poor prognostic factor for bladder cancer patients. PMID: 28621231
  17. DCLK1 induction and its overexpression following hepatic injury are likely to contribute to tumorigenesis including maintenance and dissemination of tumor cells in circulation. PMID: 27694285
  18. first evidence for the suppressive activity of miR-613 in hepatocellular carcinoma, which is causally linked to targeting of DCLK1 PMID: 27049311
  19. MSX1 and DCLK1 might be used in colorectal cancer detection or as target of cancer therapies. PMID: 27966796
  20. Increased expression of stromal DCLK1 was detected in endometriotic tissue compared to endometriosis patient endometrium. Stromal expression of DCLK1 was increased in endometrium of endometriosis patients compared to controls. PMID: 27881125
  21. DCLK1 up-regulation may play a contributory role in colorectal cancer metastasis and poor prognosis via activation of EMT. DCLK1 may serve as an independent predictor for CRC prognosis. PMID: 27520310
  22. Results showed the mechanism in which miR-137 regulates the expression of DCLK1, and demonstrated the opposite expression patterns of miR-137/DCLK1 in human non-small cell lung carcinoma and colon cancer stem cells. PMID: 26747706
  23. DCLK1 promoter methylationis associated with lung cancer. PMID: 26311076
  24. DCLK1 expression could aid in the prognostication and management of breast cancer with neuroendocrine differentiation. PMID: 26621833
  25. DCLK1 controls these complex cellular signaling pathways to regulate hepatocellular carcinoma growth, and may be used as a prognostic biomarker. PMID: 26468984
  26. results provide new insights into the molecular mechanism of the hepatitis B/C-virus induced liver inflammation and tumorigenesis via DCLK1-controlled networks PMID: 25948779
  27. Data suggest that doublecortin and CaM kinase-like 1 protein short-transcripts (DCLK1-S) may represent an important target for preventing/inhibiting colon-cancers, and for eliminating colon-cancer-stem-cells (CSCs). PMID: 26447334
  28. DCLK1 is essential for the invasive and metastatic properties of pancreatic cancer stem cells. PMID: 26764906
  29. Data indicate that doublecortin-like kinase 1 (DCLK1) is overexpressed and has a unique methylation signature in renal clear cell carcinoma (RCC). PMID: 25605241
  30. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PMID: 25723399
  31. Increased expression of DCLK1 was observed in the epithelium, stroma and plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. PMID: 25283374
  32. Potential exist for DCLK1 as a colorectal cancer biomarker for early detection, but may also have clinical implications regarding the previously proposed therapy toward DCLK1-positive cancer cells. PMID: 24384857
  33. XMD8-92 treatment results in inhibition of DCLK1 and downstream oncogenic pathways. PMID: 24880079
  34. RNA interference-mediated silencing of DCLK1 triggers apoptotic cell death of colon cancer cells in vitro and in vivo. PMID: 24626093
  35. DCLK1 mRNA levels were considerably reduced during FLV treatment. PMID: 24260365
  36. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PMID: 24040120
  37. Human pancreatic ductal adenocarcinoma cells contain morphologically and functionally distinct subpopulations, expressing DCLK1, that have cancer stem cell-like properties. PMID: 24096005
  38. DCAMKL1 represses osteoblast activation by antagonizing Runx2, the master transcription factor in osteoblasts. PMID: 23918955
  39. Dclk1 distinguishes between tumor and normal stem cells in the intestine. PMID: 23202126
  40. DCAMKL-1 marks a subset of colorectal stem cells, as well as a subset of entero-endocrine cells. PMID: 22749579
  41. the progressive increase of DCAMKL-1 expression in Barrett's esophagus from dysplasia to esophageal adenocarcinoma PMID: 21916995
  42. Several DCLK1 variants were associated with disease phenotypes for rs7989807 in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). PMID: 22539971
  43. High DCAMKL1 is associated with HCV-induced hepatocarcinogenesis. PMID: 21937640
  44. Eight suggestive significant loci were detected with a series of genes expressed within the inner ear that underlie the auditory function, such as: DCLK1, PTPRD, GRM8, CMIP. PMID: 21493956
  45. Data show that siRNA-mediated knockdown of DCAMKL-1 in pancreatic cancer cells induced microRNA miR-200a, an EMT inhibitor, along with downregulation of EMT-associated transcription factors. PMID: 21285251
  46. Together, our results suggest that silencing the DCLK splice variants DCL and DCLK-long induces apoptosis in NB cells. PMID: 20228126
  47. genomic organization underlying the splice variants of DCLK and the expression profile of two splice variants affecting the kinase domain of DCLK and CPG16 (candidate plasticity gene 16). PMID: 11884394
  48. high-quality wild-type crystals of doublecortin-like kinase were obtained and a complete native data set was collected to 1.5 A resolution PMID: 12595708
  49. an examination of the binding sites on this protein PMID: 12692530

Show More

Hide All

Protein Families
Protein kinase superfamily, CAMK Ser/Thr protein kinase family, CaMK subfamily
Tissue Specificity
In fetal tissues, highly expressed in brain, detectable in lung and liver, but not in kidney. In adult tissues, expressed ubiquitously in the brain, detectable in the heart, liver, spleen, thymus, prostate, testis, ovary, small intestine and colon. The ty
Database Links

HGNC: 2700

OMIM: 604742

KEGG: hsa:9201

STRING: 9606.ENSP00000255448

UniGene: Hs.507755

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*